Prescribing BiDil: is it black and white?
Journal Article (Journal Article)
The approval of BiDil as an adjunct treatment in self-identified blacks with heart failure raises questions regarding the underlying etiology of drug response in this target population and the ability to accurately identify patients who are most likely to benefit. Preliminary data have indicated that differences in nitric oxide synthesis between groups may account for differences in response to BiDil and genetic studies have begun to elucidate the mechanism of these differences. Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil.
Full Text
Duke Authors
Cited Authors
- Haga, SB; Ginsburg, GS
Published Date
- July 4, 2006
Published In
Volume / Issue
- 48 / 1
Start / End Page
- 12 - 14
PubMed ID
- 16814642
Electronic International Standard Serial Number (EISSN)
- 1558-3597
Digital Object Identifier (DOI)
- 10.1016/j.jacc.2006.04.017
Language
- eng
Conference Location
- United States